Great Point Partners LLC Tg Therapeutics, Inc. Transaction History

Great Point Partners LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2020 Feb 16, 2021	SELL	$25.27 - $54.9 $40.4 Million - $87.8 Million	-1,600,000 Closed	0 $0
Q3 2020 Nov 16, 2020	SELL	$18.49 - $27.24 $31.8 Million - $46.9 Million	-1,720,808 Reduced 51.82%	1,600,000 $42.8 Million
Q2 2020 Aug 14, 2020	BUY	$8.9 - $21.84 $6.8 Million - $16.7 Million	764,484 Added 29.91%	3,320,808 $64.7 Million
Q1 2020 May 15, 2020	SELL	$7.14 - $15.99 $20.6 Million - $46 Million	-2,878,459 Reduced 52.96%	2,556,324 $25.2 Million
Q4 2019 Feb 14, 2020	BUY	$5.1 - $11.2 $27.7 Million - $60.9 Million	5,434,783 New	5,434,783 $60.3 Million
Q1 2019 May 14, 2019	SELL	$4.02 - $8.04 $12.1 Million - $24.1 Million	-3,000,000 Closed	0 $0
Q4 2018 Feb 15, 2019	BUY	$3.44 - $5.76 $3.61 Million - $6.05 Million	1,050,000 Added 53.85%	3,000,000 $12.3 Million
Q3 2018 Nov 14, 2018	BUY	$5.15 - $14.0 $10 Million - $27.3 Million	1,950,000 New	1,950,000 $10.9 Million

349

89.5M

2.35M

1.7M

Ticker TGTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 145,274,000
Market Cap $4.61B
Description
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hod...

Get notified when there are updates to the investment portfolio of Great Point Partners LLC, based on Form 13F filings with the SEC.

Stay updated on Great Point Partners LLC with notifications on news.